Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock

Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten public offering of 3,125,000 shares of its common stock at a price to the public of $96.00 per share. All of the shares of common stock to be sold in the public offering are to be sold by Twist. The gross proceeds to Twist from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $300.0 million. In addition, Twist has granted the underwriters a 30-day option to purchase up to an additional 468,750 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on August 6, 2026, subject to the satisfaction of customary closing conditions.